Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

123.76 -1.69 (-1.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short o... 
Via StockStory
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
U.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health ↗
Via Chartmill
News headline image
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
From Gilead Sciences, Inc.
Via Business Wire
News headline image
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial ↗
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends 
Via Benzinga
News headline image
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
From Merck & Co., Inc.
Via Business Wire
News headline image
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead ↗
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming... 
Via MarketBeat
News headline image
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands ↗
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease... 
Via MarketBeat
News headline image
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH? ↗
Compare diversification strategies and see how each ETF's unique index focus shapes risk and return for healthcare sector investors. 
Via The Motley Fool
Topics ETFs
News headline image
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome ↗
Gilead reports positive Phase 3 Livdelzi data in PBC, with more patients achieving ALP normalization versus placebo after 52 weeks. 
Via Benzinga
News headline image
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
If You Invested $1000 In Gilead Sciences Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC... 
Via MarketBeat
News headline image
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
From Gilead Sciences, Inc.
Via Business Wire
News headline image
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Compugen Q1 Earnings Call Highlights ↗
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company... 
Via MarketBeat
Topics Earnings
News headline image
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline ↗
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and... 
Via MarketBeat
News headline image
3 Market-Beating Stocks to Research Further
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.